Dermatologists Discuss the FDA Approval of Baricitinib for Alopecia Areata
June 16, 202222m 38s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
On June 13, the US Food and Drug Administration (FDA) approved oral baricitinib (Olumiant) tablets for the treatment of severe alopecia areata in adults, which marked the first approval of a systemic treatment for the disorder.
The approval has excited patients and providers alike who struggled for decades to treat severe cases of this autoimmune disorder.
For this episode of DocTalk, several key opinion leaders in the dermatology field sound off on the implications of this decision, as well as the versatility of Janus kinase (JAK) inhibitors, and how this approval will aid providers in redefining alopecia areata as an autoimmune disorder rather than simply a cosmetic condition, which will help more patients receive proper care.
Joining us on the podcast and in written form are the following dermatologists:
- Brett King, MD, PhD, Yale School of Medicine, New Haven
- Lisa Arkin, MD, member of the Society for Pediatric Dermatology, University of Wisconsin School of Medicine & Public Health / American Family Children's Hospital.
- Karan Lal, DO, MS, FAAD, Schweiger Dermatology Group and member of The Society for Pediatric Dermatology
- Brittany Craiglow, MD, Yale School of Medicine, New Haven